Payment overview · 2025
General Payments
$486.96
20 reported records · 13 companies
Healthcare provider profile · identity verified
John Matthew Rainey, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · EUNICE, LA · NPI 1073724514
Verified facts
What the public records show
CMS Open Payments records show John Matthew Rainey, M.D. received $486.96 in general payments during 2025 across 20 reported records.
Novo Nordisk Inc accounted for 25.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Jardiance by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $124.99 | 25.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $91.22 | 18.7% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $59.39 | 12.2% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $32.02 | 6.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $30.67 | 6.3% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $30.65 | 6.3% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.19 | 4.2% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $18.11 | 3.7% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $18.09 | 3.7% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.92 | 3.3% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.79 | 3.2% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $15.71 | 3.2% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.21 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $486.96 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $67.44 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $67.44 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $59.39 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $48.74 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $32.02 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $30.67 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $30.67 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $23.78 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $20.19 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $18.11 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.92 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $15.79 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $15.71 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $14.21 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 132 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 68 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
51 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
132 | 22 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
68 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 668 | 132 |
| Atorvastatin Calcium | Atorvastatin Calcium | 571 | 124 |
| Furosemide | Furosemide | 426 | 93 |
| Omeprazole | Omeprazole | 404 | 81 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 393 | 76 |
| Gabapentin | Gabapentin | 367 | 70 |
| Levothyroxine Sodium | Levothyroxine Sodium | 330 | 62 |
| Lisinopril | Lisinopril | 279 | 52 |
| Pantoprazole Sodium | Pantoprazole Sodium | 274 | 57 |
| Losartan Potassium | Losartan Potassium | 259 | 54 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 252 | 58 |
| Metformin Hcl | Metformin Hcl | 247 | 51 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 237 | 49 |
| Sertraline Hcl | Sertraline Hcl | 182 | 29 |
| Tramadol Hcl | Tramadol Hcl | 173 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 165 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 164 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 159 | 32 |
| Benazepril Hcl | Benazepril Hcl | 158 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 157 | 31 |
| Carvedilol | Carvedilol | 150 | 30 |
| Simvastatin | Simvastatin | 141 | 19 |
| Lovastatin | Lovastatin | 140 | 28 |
| Famotidine | Famotidine | 138 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 136 | 21 |
| Jardiance | Empagliflozin | 132 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 131 | 25 |
| Trazodone Hcl | Trazodone Hcl | 130 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 120 | 24 |
| Tizanidine Hcl | Tizanidine Hcl | 117 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 115 | 51 |
| Potassium Chloride | Potassium Chloride | 115 | 30 |
| Alendronate Sodium | Alendronate Sodium | 114 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 113 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 112 | 21 |
| Glipizide | Glipizide | 110 | 20 |
| Donepezil Hcl | Donepezil Hcl | 103 | 23 |
| Buspirone Hcl | Buspirone Hcl | 101 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 99 | 17 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 98 | 21 |
| Prednisone | Prednisone | 97 | 71 |
| Allopurinol | Allopurinol | 96 | 25 |
| Chlorthalidone | Chlorthalidone | 94 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 93 | 26 |
| Januvia | Sitagliptin Phosphate | 89 | suppressed |
| Mirtazapine | Mirtazapine | 87 | 15 |
| Finasteride | Finasteride | 77 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 76 | 21 |
| Clonazepam | Clonazepam | 75 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 74 | 19 |
| Montelukast Sodium | Montelukast Sodium | 74 | 18 |
| Azithromycin | Azithromycin | 73 | 63 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 73 | 15 |
| Memantine Hcl | Memantine Hcl | 70 | 17 |
| Ozempic | Semaglutide | 68 | 16 |
| Meloxicam | Meloxicam | 67 | 15 |
| Baclofen | Baclofen | 66 | 11 |
| Eliquis | Apixaban | 66 | 12 |
| Diazepam | Diazepam | 64 | 15 |
| Xarelto | Rivaroxaban | 63 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 62 | suppressed |
| Atenolol | Atenolol | 59 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 58 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 57 | 15 |
| Alprazolam | Alprazolam | 53 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 53 | 13 |
| Linzess | Linaclotide | 51 | 14 |
| Clonidine Hcl | Clonidine Hcl | 48 | 12 |
| Nabumetone | Nabumetone | 48 | 15 |
| Mounjaro | Tirzepatide | 47 | suppressed |
| Celecoxib | Celecoxib | 46 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 45 | suppressed |
| Trulicity | Dulaglutide | 44 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 43 | suppressed |
| Methylprednisolone | Methylprednisolone | 43 | 36 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 43 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 43 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 41 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 41 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 41 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 41 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 41 | 36 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 40 | 34 |
| Sucralfate | Sucralfate | 40 | 13 |
| Ibuprofen | Ibuprofen | 39 | 11 |
| Mupirocin | Mupirocin | 38 | 31 |
| Ventolin Hfa | Albuterol Sulfate | 38 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 37 | suppressed |
| Lorazepam | Lorazepam | 37 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 36 | 17 |
| Fenofibrate | Fenofibrate Nanocrystallized | 36 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 36 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 35 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 35 | 20 |
| Levofloxacin | Levofloxacin | 34 | 28 |
| Paroxetine Hcl | Paroxetine Hcl | 34 | suppressed |
| Spironolactone | Spironolactone | 34 | suppressed |
| Glipizide Er | Glipizide | 33 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 33 | suppressed |
| Torsemide | Torsemide | 33 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 27 |
| Colchicine | Colchicine | 32 | 14 |
| Valacyclovir | Valacyclovir Hcl | 32 | 18 |
| Venlafaxine Hcl | Venlafaxine Hcl | 32 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 31 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 30 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 30 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 30 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 29 | 12 |
| Gemfibrozil | Gemfibrozil | 29 | suppressed |
| Methocarbamol | Methocarbamol | 29 | suppressed |
| Nystatin | Nystatin | 28 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 28 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 27 | suppressed |
| Entresto | Sacubitril/Valsartan | 27 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 27 | suppressed |
| Roflumilast | Roflumilast | 27 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 26 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 26 | 23 |
| Hydrocortisone | Hydrocortisone | 26 | 16 |
| Methotrexate | Methotrexate Sodium | 26 | suppressed |
| Ramipril | Ramipril | 25 | suppressed |
| Tradjenta | Linagliptin | 25 | suppressed |
| Latanoprost | Latanoprost | 24 | suppressed |
| Lubiprostone | Lubiprostone | 24 | suppressed |
| Primidone | Primidone | 24 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 23 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 23 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 22 | suppressed |
| Cefdinir | Cefdinir | 22 | 22 |
| Ibandronate Sodium | Ibandronate Sodium | 22 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 22 | suppressed |
| Pregabalin | Pregabalin | 22 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 22 | 11 |
| Estradiol | Estradiol | 21 | suppressed |
| Glimepiride | Glimepiride | 21 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Klor-Con M20 | Potassium Chloride | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Temazepam | Temazepam | 20 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 19 | suppressed |
| Fluconazole | Fluconazole | 18 | 14 |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Metronidazole | Metronidazole | 18 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Ofloxacin | Ofloxacin | 17 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 16 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 16 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 14 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 13 | suppressed |
| Prenatal Vitamin Plus Low Iron | Pnv,calcium 72/Iron/Folic Acid | 13 | suppressed |
| Vraylar | Cariprazine Hcl | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | 12 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Levetiracetam Er | Levetiracetam | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Ursodiol | Ursodiol | 12 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Ezetimibe | Ezetimibe | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Hydroxyurea | Hydroxyurea | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $486.96 · 20 records | Novo Nordisk Inc | BREZTRI, FANAPT, JARDIANCE, Kerendia, LEQVIO, OTEZLA, Ozempic, QULIPTA, Qelbree, REPATHA, REXULTI, UBRELVY, VRAYLAR, XIFAXAN, YUPELRI | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error